Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q4
SJR
0.252
CiteScore
2.2
Categories
Neurology
Neurology (clinical)
Psychiatry and Mental Health
Areas
Medicine
Neuroscience
Years of issue
2017, 2019-2025
journal names
Sleep and Vigilance
Top-3 citing journals

Sleep and Vigilance
(36 citations)

Journal of Clinical Medicine
(17 citations)
Top-3 organizations

All India Institute of Medical Sciences, Rishikesh
(24 publications)

All India Institute of Medical Sciences, Delhi
(19 publications)

All India Institute of Medical Sciences, Bhopal
(14 publications)

All India Institute of Medical Sciences, Rishikesh
(19 publications)

All India Institute of Medical Sciences, Delhi
(14 publications)

Shree Guru Gobind Singh Tricentenary University
(13 publications)
Most cited in 5 years
Found
Publications found: 1126
Q4

Apoptotic effects of crude muscle extract from marine pufferfish Chelonodon patoca against human cancer cell lines
Sekar N., Valayapathi R., Azhagudurai A., Durai P., Selvakumar S.S., Chinnasamy A.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
The global establishment of cancer registries has prompted a hunt for innovative medications that destroy cancer but not healthy cells. Researchers are currently searching marine environments for new anticancer drugs. Modern chemotherapy uses numerous compounds of aquatic origin. These substances exhibit cytotoxic characteristics through various methods, including DNA damage, apoptosis induction, and growth suppression of cancerous cells. The discovery and development of novel anticancer agents from abundant marine fish is generating increasing interest. The objective of this present study is to extract and assess the anti-proliferative effect of a crude muscle extract from marine pufferfish on human cancer cell lines.
Methods
The biochemical constituents, protein profile, and anticancer activities of the prepared crude muscle extract were analysed using standard methods on human cancer cell lines (HT-29, MDA-MB-231, A-549, and AGS).
Results
The biochemical contents, such as protein (7.19 ± 0.20 mg/mL), lipid (1.56 ± 0.14 mg/mL), and carbohydrate (1.19 ± 0.09 mg/mL), were quantitatively analysed. Native PAGE and SDS-PAGE qualitatively analysed the protein profiles, revealing distinct protein bands with molecular weights ranging from 220 to 14 kDa. The crude muscle extract was screened for its cytotoxicity (vero) and cell viability (HT-29, MDA-MB-231, A-549, and AGS) against human cancer cell lines by the MTT assay method. The nuclear morphological changes of the apoptotic cells were stained using propidium iodide, and the morphological changes associated with apoptosis were assessed using acridine orange/ethidium bromide (AO/EB) fluorescence staining. The intensity of the mitochondrial membrane potential of the treated cells was measured using the Rh-123 stain, and the results of the DNA fragmentation assay showed that the crude muscle extract-treated cells showed DNA damage, which is indicative of apoptosis.
Conclusions
This preliminary study supports that the crude muscle extract from milk spotted marine pufferfish, C. patoca has strong anticancer properties. This implies potential for the development of more effective anticancer drugs in future.
Graphical abstract
Q4

Investigating the expression level of 9-methylated septin 9 in different grades of colorectal cancer—a meta-analysis study
Mohandesi khosrosroshahi E., Bashi Zadeh Fakhar H., Akbari M., Izadi N.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Introduction
Colorectal cancer (CRC) is a leading cause of cancer mortality in the USA, highlighting the urgent need for early detection. Methylated septin 9 (mSEPT9) is a promising tumor marker for CRC, offering high sensitivity for early stage detection, but its use in Asia is limited.
Method
We conducted a systematic review of empirical quantitative studies on mSEPT9 gene in cell-free DNA collected from plasma in CRC, following PRISMA and Cochrane guidelines, with searches yielding 1,340 records, of which 13 met our inclusion criteria. Quality was assessed using the STROBE checklist, ensuring robust data extraction and analysis.
Result
A total of 13 quantitative studies analyzed showed an overall positive detection rate of 66.98% for mSEPT9 as a diagnostic test for colorectal cancer, with the highest detection rate of 99.99% in Stage IV and the lowest at 51.21% in Stage I.
Conclusion
Our study demonstrates that mSEPT9 gene expression was a key biomarker for diagnosing and staging CRC, with higher detection rates in advanced stages, particularly Stage IV. Its role in critical signaling pathways highlights its potential for improving early detection and treatment planning in CRC patients.
Q4

Blood group diversity in Borneo
Assyuhada M.G., Hajar C.G., ‘Adani S.N., Hassan M.N., Mohammad Isa N.S., Ali N.S., Mohamad S.A., Aziz M.Y., Furqoni A.H., Chambers G.K., Zulkafli Z., Edinur H.A.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
Protein and glycoprotein antigens on the surface of red blood cells are encoded by highly polymorphic genes in human nuclear genomes. Allelic variants of the blood group genes are known to be distributed differently across populations. Consequently, they are widely used for ancestral analyses and for designing donor recruitment strategies. In Malaysia, blood group allele frequency population data are available for many population groups in Peninsular Malaysia, but not for those from Sabah and Sarawak of Borneo. Thus, this study contributes to a wider systematic collection of blood group data and expands the range of analyses.
Aim
This study determined the allele frequencies of nine clinically significant blood group systems (Kell, Kidd, Duffy, MNS, Dombrock, Colton, Lutheran, Cartwright and Vel) in the Bajau, Kadazan-Dusun, Murut and Melanau populations of Borneo.
Results
Many of the blood group systems examined here are polymorphic in the Bajau, Kadazan-Dusun, Murut and Melanau except for Kell, Colton, Lutheran, Cartwright and Vel. Population data mapping shows that these four populations are more closely related to other Austronesian populations, than other linguistically and historically unrelated population groups in Malaysia and elsewhere.
Conclusions
In this study, we have successfully typed variants that determine Kell, Kidd, Duffy, MNS, Dombrock, Colton, Lutheran, Cartwright and Vel blood group systems in the samples collected from unrelated Bajau, Kadazan-Dusun, Murut and Melanau individuals of Borneo. Many of these blood group systems were observed to be polymorphic in these populations. These findings are similar to those reported for other population groups in Peninsular Malaysia. Clinical complications that are more likely to arise in these people (gestation and transfusion alloimmunizations as well as risk to diseases) should be considered by health practitioners, healthcare providers and healthcare policy makers based on our observations.
Graphical abstract
Q4

lncRNA FLVCR1-AS1 sponges miR-381-3p and promotes Wnt signaling pathway resulting in colorectal cancer progression
Ahmadi Beni F., Abdolvand M., poorbafrani F., Salehi M., Dehghanian F., Kazemi M.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
Colorectal cancer (CRC) is the third most frequent cancer and the second deadliest cancer, worldwide. Long noncoding RNAs (lncRNAs) have been introduced as crucial regulators of CRC. lncRNA feline leukemia virus subgroup C receptor 1 antisense RNA 1 (FLVCR1‑AS1) is suggested to play a significant role in the tumorigenesis of several cancers. The Wnt signaling pathway is the most deregulated pathway in CRC.
Objective
The present study aimed to investigate the underlying mechanism of function of FLVCR1-AS1 in CRC through FLVCR1-AS1/miR-381-3p/CTNNB1, LRP6, and FZD3 axis.
Methods
The expression levels of FLVCR1-AS1 were analyzed in colorectal cancer (CRC) tissues compared to adjacent normal tissues, as well as across various CRC cell lines. In HCT116 cells, FLVCR1-AS1 was knocked down, and the subsequent effects on the expression levels of FLVCR1-AS1, miR-381-3p, and three genes were measured using real-time PCR. Proliferation differences were assessed through an MTT assay, while cell death was evaluated using flow cytometry.
Results
The results confirmed that FLVCR1-AS1 was upregulated in CRC tissues compared to adjacent normal tissues. RT-qPCR validated that FLVCR1-AS1 has the most level of expression in HT29, HCT116, SW480, and Caco2; respectively. Knockdown of FLVCR1‑AS1 was significantly followed by attenuated viability of HCT116 cells; while resulted in enhancement of apoptosis and necrosis.
Conclusion
These findings support the idea that FLVCR1-AS1 may act as an oncogene in CRC, and targeting FLVCR1-AS1/miR-381-3p/CTNNB1, LRP6, and FZD3 axis may be introduced as a novel target for CRC therapy and diagnosis in the future.
Q4

Adoptive transfer of natural killer cells in therapeutic treatment of COVID-19 patients
Alamri A.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
Natural killer (NK) cells are crucial constituents of innate immunity, playing a vital role in the early defense against viral infections and cancer. Their antiviral capabilities stem from direct cytotoxic activity against infected cells and immunoregulatory functions that modulate adaptive immune responses. In the context of Coronavirus disease (COVID-19), NK cells contribute to controlling viral replication and limiting excessive inflammatory responses.
Aims
This review highlights the mechanisms underlying NK cell-mediated antiviral activity, focusing on their interactions with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). We discuss potential sources of NK cells for adoptive transfer therapy, critical factors influencing their therapeutic efficacy, and considerations for clinical translation in COVID-19 treatment.
Methods
Various NK cell sources for adoptive therapy are discussed, including peripheral blood, cord blood, and genetically engineered NK cells. Key factors influencing the therapeutic efficacy and safety of NK cell-based therapies are analyzed, including cytokine modulation, NK cell subset selection, and delivery methods.
Conclusion
Understanding the mechanisms underlying NK cell-mediated antiviral activity and the factors that influence the success of adoptive NK cell therapy can inform the design of more effective immunotherapies for COVID-19 patients. Strategies for improving NK cell function, such as genetic modification and optimizing therapy protocols, are highlighted to enhance therapeutic outcomes.
Graphical Abstract
NK cells neutralize SARS-CoV-2 by releasing cytotoxic granules, inhibiting replication, and modulating inflammation. They originate from peripheral blood, cord blood, and genetic engineering. Therapeutic strategies include adoptive transfer, cytokine modulation, and optimized delivery. Inflammation is controlled, reducing excessive immune responses.
Q4

FOXF2 rs41300825 and NOTCH3 rs1043994 as risk loci for cerebral small vessel disease in Egyptian ischemic stroke patients
Hussein F.S., Sayed S.S., Mohammed H.S., Kamal M.M.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
Cerebral small vessel disease (CSVD) is a significant cause of ischemic stroke in all ethnic groups. Genetic determinants of CSVD are poorly understood and have rarely been explored. One proposed mechanism behind SVD is the breakdown of the blood–brain barrier (BBB). An intact barrier relies heavily on appropriate pericyte (PC) coverage of BBB endothelial cells. FOXF2 and NOTCH3 are two genes implicated in PC development and maintenance, thus influencing PC coverage of brain blood vessels. The aim of this study is to investigate whether FOXF2 rs41300825 and NOTCH3 rs1043994 variants can be considered as candidate loci for CSVD in Egyptian patients, marking the first study of its kind in Egypt.
The present study included 186 ischemic stroke patients, selected from neurology and psychiatry department at Ain Shams University hospitals. Patients were categorized into: Group I (SVD patients; n = 114) and Group II (LVD patients; n = 72). Genotyping was conducted for FOXF2 rs41300825 (G/C) and NOTCH3 rs1043994 (A/G/T) using RFLP-PCR, with results confirmed through Sanger sequencing and multiple alignments of sequencing using the MEGA X program.
Results
Results showed that genotype analysis for FOXF2 rs41300825 displayed one band of 334 bp, indicating the GG genotype. The same was observed for NOTCH3 rs1043994 with one band of 665 bp, representing the GG genotype. Sanger sequencing and multiple alignments of sequencing using the MEGA X program confirmed the results.
Conclusion
Neither FOXF2 rs41300825 nor NOTCH3 rs1043994 were able to differentiate between patients at risk of developing SVD and those susceptible to LVD. Further studies with larger sample sizes are necessary.
Q4

Unraveling the structural and functional consequences of non-synonymous single-nucleotide polymorphisms (nsSNPs) in human SOCS2: an in silico approach
Hossain T., Islam M.N., Hossain M.A., Rahman M.M., Islam M.M., Gupta S.D.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
The protein from suppressors of cytokine signaling (SOCS) family regulates immune response by modulating the signaling pathways of cytokines. SOCS2, a member of this family, plays an important role in regulating growth hormone receptors, the JAK-STAT pathway, energy homeostasis, and other biological processes. Multiple non-synonymous SNPs (nsSNPs) have been found in the SOCS2 gene, which could affect protein function. However, there is limited understanding of disease susceptibility and abnormal functioning associated with these mutated SOCS2 gene.
Results
In this study, we examined nsSNPs in the human SOCS2 gene to evaluate their effects on protein stability, structure, and function through in silico approaches. SIFT; PhD-SNP, PROVEAN, PMut, PANTHER, PolyPhen-2, SNPs&GO, I-Mutant 3.0, and MUpro were the bioinformatics tools used to forecast the most harmful SNPs. ConSurf found the eight nsSNPs (L71F, G102R, G51E, G47R, R96Q, Y49H, P155Q, and I171S) to be present in highly conserved region, thus affecting their protein stability. The Project HOPE analysis predicts the 3D structure of the eight respective mutated proteins and assesses their potential molecular impact on protein function and structure. After a series of analysis, three mutants (G47R, Y49H, and I171S) were subjected to molecular dynamic simulation, principal component analysis, and free energy landscape to understand their impact during the course of mutation. The STRING algorithm was used to predict protein–protein interactions. Finally, KM plotter analysis showed that deregulation of SOCS2 gene expression has a significant impact on the patients’ survival rate of different types of cancers.
Conclusion
Our study has identified the eight most high-risk SNPs of SOCS2 gene that may contribute to diseases development associated with growth hormone signaling, immune dysregulation, and other energy metabolism.
Q4

Assessing the association of rare MDR1 variants (rs944806668, rs1816042256, and rs1295312177) with steroid response in Iraqi children with idiopathic nephrotic syndrome
Abd Alridha A.M., Kadhim D.J., Alkhazrajy A.H.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
Several studies have linked the development of steroid-resistant nephrotic syndrome (SRNS) to variations in the multidrug resistance 1 gene (MDR1). However, disparities in findings have been noted among children of different ethnic origins.
Objectives
This study aimed to examine the relationship between MDR1 variants [rs944806668 (V1), rs1816042256 (V2), and rs1295312177 (V3)] and the risk of developing SRNS in Iraqi patients with idiopathic nephrotic syndrome (INS).
Methods
This case–control study included children with steroid-sensitive INS (n = 30) and SRNS (n = 30) from the Babylon Hospital for Maternity and Pediatrics. Sanger sequencing was used to determine the participants’ genotypes.
Results
Children with the V2 T/C genotype were more likely to develop SRNS [odds ratio (OR) and 95% confidence interval (95% CI): 10.8 (3.26–35.72), p < 0.001] than those with the wild genotype. However, no significant association with steroid response was observed for the V1 genotypes and alleles [OR (95% CI): 0.58 (0.18–1.91) and 0.63 (0.21–1.9), respectively; p > 0.05]. Moreover, children with the wild–variant–variant genotype combination of the V1, V2, and V3 variants exhibited a significantly higher risk of developing SRNS [OR (95% CI) 34 (4.91–235.61), p < 0.001] than those with the wild–wild–wild genotype combination.
Conclusion
These findings highlight the need to incorporate pharmacogenetic screening into the clinical management of SRNS. Children with nephrosis having the V2 T/C and V3 A/T genotypes, whether individually or in combination, are likely to resist prednisolone therapy, implying the need for alternative therapeutic approaches. Further studies are required to elucidate the potential implications of MDR1 variants for personalized drug therapy in children with INS.
Q4

Whole-exome sequencing and molecular dynamics confirm pathogenicity of a novel SLC6A6 mutation in Leber congenital amaurosis
Natarajan S.N., Ansar S., Sripriya S., Parveen S., Gupta R., Vetrivel U., Sinnakarupan M.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Introduction
Inherited retinal diseases (IRDs) are a clinically and genetically heterogenous group where the robust advancement of next-generation sequencing technologies has facilitated genotype-assisted diagnosis. Leber congenital amaurosis (LCA) is a severe form of inherited retinal dystrophy that causes congenital blindness or near-blindness with a global prevalence of 3 per 100,000 live births.It is characterized by a loss of vision at birth or within the first few years of life with overlapping phenotypes to many syndromic and non-syndromic IRDs. With India's rich genetic heterogeneity, WES is a valuable tool for uncovering novel gene mutations linked to LCA. This genetic diversity expands our understanding of the disease's spectrum in the Indian population.
Methods
In our previous study, 92 Indian LCA families were screened through targeted resequencing, and 80% of probands exhibited mutations in known genes. Hence, the remaining 20% probands with additional family members (n = 40) were subjected to whole-exome sequencing. An in-house standard bioinformatics pipeline was used for variant calling and annotation. Homology modeling (Modeller-9.23) and molecular simulation were performed on an identified SLC6A6 gene variant that has not yet been associated with LCA to investigate its potential pathogenicity.
Results
Disease-causing pathogenic variants were identified in 15/20 families (75%) across 11 genes with 33% variants being novel. Among the identified 17 variants in 15 families, 35% were missense, 29% nonsense, 29% frameshift and 6% splice variants. Segregation analysis, control screening and in silico predictions confirmed the variant’s pathogenicity. All variants were classified as pathogenic according to ACMG guidelines. Homology modeling and molecular simulation in the membrane system for the p.Pro82Leu mutant in SLC6A6 protein showed significant modification in helical characteristics around the TM2 helix in the mutant, which could potentially hinder the regular function and cause disruption in taurine transport across the membrane leading to the disease.
Conclusion
Taurine being an essential amino acid for photoreceptor development and maintenance, our study suggests that mutation identified in SLC6A6 gene may cause LCA. This is the first report of SLC6A6 gene association with LCA and also the first case report in the Indian population.
Q4

Evaluation of pathogenic variant in WFS1 in a patient with Wolfram syndrome
Hoseinzadeh M., Jahani M.M., Nasrniya S., Tabatabaiefar M.A.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Objective
Wolfram syndrome (WS) is a genetically disorder that affect on many organs, and neurodegenerative disorder. Although various clinical dysfunctions may have different onset times, they can collectively contribute to delays in the diagnosis of the disorder. To date, more than 200 pathogenic and likely pathogenic variant have been identified. In the present investigation, we evaluated three families with WS and reported a mutation in the WFS1.
Methods
This study, we have evaluated mutation in the WFS gene in three consanguineous families including three patients with a history of young-onset DM, progressive hearing loss and optic atrophy further neurological abnormalities.
Results
Sequencing results showed a novel homozygous stop-gain variant, c.1444A > T (p.K482X), and two previously reported mutations (c.2006A > G and c.2105G > A) in exon 8 of WFS1 gene. The variant interpretation was done according to the genetic guidelines. Finally, p.K482X was determined as a novel pathogen variant. Also, analysis showed that variants in parents were heterozygous.
Conclusions
The present survey, revealed a novel nonsense mutation in the wolframin protein, creates a frameshift which causes a premature stop codon truncating the protein in amino acid 482 residues. This mutation occurs in transmembrane domain and causes elimination of 46% of wolframin protein.
Q4

Unveiling the association between long non-coding RNAs (RP5-833A20.1, DYNLRB2-2, and APOA1-AS) and ischemic stroke: exploring biomarkers, and clinical implications
Bayat M., Mokhtari M., Mokhtari M.J., Gharbi N., Tabrizi R., Salehi M.S., Karimi N., Rahimi M., Hooshmandi E., Zafarmand S.S., Owjfard M., Lashanizadegan R., Dara M., Borhani-Haghighi A.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
RP5-833A20.1, DYNLRB2-2, and APOA1 antisense are pivotal in atherosclerotic plaque pathogenesis. This study examined whether changes in these circulating lncRNAs could serve as biomarkers for high-risk ischemic stroke (IS) patients with intracranial atherosclerotic disease (ICAD).
Methods
Sixty-three IS patients, presenting within the first 24 h after stroke onset, and 60 controls were included in the study. The circulating levels of RP5-833A20.1, DYNLRB2-2, and APOA1 antisense in IS patients were assessed using real-time polymerase chain reaction (RT-PCR).
Results
Significant decreases in the circulating levels of DYNLRB2-2 and RP5-833A20.1 were observed in IS patients compared to controls (P < 0.05). However, no significant difference in APOA1 antisense levels was noted between the two groups. Subgroup analysis revealed higher RP5-833A20.1 expression in IS patients with lower National Institutes of Health Stroke Scale (NIHSS) scores (0–6) compared to those with higher scores (3.59 ± 0.783 vs. 1.05 ± 0.505, P = 0.006). After adjusting for relevant covariates, multiple logistic regression indicated an inverse association between RP5-833A20.1 and the risk of IS (adjusted OR = 0.846, P = 0.028). Linear regression analyses further demonstrated a negative correlation between RP5-833A20.1 expression and NIHSS (beta = − 0.398, P = 0.006), which was confirmed by a significant negative Spearman correlation (r = − 0.41, P = 0.0007). DYNLRB2-2 exhibited a non-significant negative relationship with NIHSS.
Conclusion
The findings suggest a significant decrease in the circulating levels of RP5-833A20.1 and DYNLRB2-2 in IS patients with ICAD, potentially indicating a protective effect against ischemic stroke. These lncRNAs hold promise as valuable biomarkers for identifying high-risk IS patients, emphasizing the need for further exploration and validation in larger cohorts to elucidate their roles in IS pathogenesis and clinical applications.
Q4

Exploring the effects of alpha-pinene on apoptosis induction in human colon cancer cells via the PI3K/AKT signaling pathway: an in vitro study
Shafieipour S., Zamanian Y., Hadipour E., Sinaei R., Khoshnazar S.M.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
Colorectal carcinoma ranks as the second most prevalent neoplasm in females and the third most prevalent in males.
Methods
In this investigation, we examined the influence of alpha-pinene (ALP), classified as a monoterpene, on the proliferation of HT-29 human colorectal carcinoma cells via the PI3K/AKT signaling cascade. HT-29 cells were exposed to a range of ALP concentrations. The survival rate of the cells was assessed through the MTT assay; while, apoptotic events were evaluated using flow cytometry in conjunction with Annexin V/PI staining. Additionally, cell cycle dynamics were scrutinized through fluorescence-activated cell sorting. The expression levels of Bax, Bcl-2, Caspase-3, PI3K, and AKT at both the gene and protein levels were quantified employing real-time PCR and western blot techniques.
Results
ALP treatment led to a significant, dose-dependent decrease in cell viability, with prolonged exposure exacerbating cytotoxic effects. Apoptosis analysis showed that ALP significantly increased apoptotic cells after 24 h of treatment. Cell cycle analysis showed that ALP induces G2/M phase arrest and inhibits cell proliferation and DNA synthesis. Gene expression analysis revealed upregulation of pro-apoptotic genes Bax and caspase-3 and decreased anti-apoptotic gene Bcl-2. Furthermore, the administration of ALP led to a notable reduction in both the gene and protein expression levels of PI3K and Akt, suggesting a suppression of the PI3K/Akt signaling cascade.
Conclusion
ALP inhibits HT-29 colon cancer cell growth by reducing cell viability, inducing apoptosis, and blocking the PI3K/AKT pathway. These findings highlight ALP’s potential as a therapeutic candidate for colorectal cancer.
Q4

Unraveling relationship between the genetic polymorphism CYP2A13 and nicotine metabolism of male smokers in Medan, Indonesia
Soeroso N.N., Zain-Hamid R., Bihar S., Soliha C., Ananda F.R., Aida
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
Nicotine metabolism significantly influences the levels of harmful nicotine metabolites in smokers. CYP2A13, a key enzyme in nicotine and xenobiotic metabolism, is implicated in tobacco smoke-related lung cancer.
Aim
This study investigated the association between CYP2A13 genetic polymorphism and nicotine metabolism in male smokers in Medan, Indonesia.
Materials and methods
This cross-sectional study included 66 male smokers (aged 20–65 years) who met pre-defined inclusion and exclusion criteria. Nicotine metabolite levels were quantified in urine samples using high-performance liquid chromatography (HPLC). CYP2A13 polymorphism was determined using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) analysis of venous blood samples. Logistic regression analysis (Epi Info-7) assessed the association between CYP2A13 genotype and nicotine metabolism.
Results
No significant association (p > 0.05) was found between CYP2A13 genotype and nicotine metabolism. The CC genotype was most prevalent. The majority of participants exhibited rapid nicotine metabolism.
Conclusion
Further research with larger sample sizes and diverse populations is needed to elucidate the relationship between CYP2A13 genetic polymorphism and nicotine metabolism.
Q4

Preimplantation aneuploidy screening using embryonic cell-free DNA isolated from spent culture medium: a case report
Khudari L., Halabi M., Al Fahoum S.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
Chromosomal aberrations are frequent in human embryos and can be identified during IVF by performing preimplantation genetic testing for aneuploidies (PGT-A). Therefore, this study presents a case report highlighting the application of embryonic cell-free DNA isolated from spent culture medium for preimplantation aneuploidy screening.
Case presentation
This case report elucidates the potential use of non-invasive preimplantation genetic testing for aneuploidy (PGT-A) as a valuable resource for couples facing infertility challenges. By using PGT-A, these couples can assess the genetic health of embryos before implantation, thereby increasing the chances of a successful pregnancy through assisted reproductive technologies.
Conclusions
PGT-A, an innovative technique using embryonic cell-free DNA isolated from a spent culture medium, offers a non-invasive and effective method for assessing chromosomal aberrations in embryos. It has the potential to enhance preimplantation genetic testing and support medically personalized embryo selection.
Q4

Association between CAPN-10 gene variant and diabetes mellitus in Nigeria: a review
Adebo D.O., Olaniyan M.F., Ugege C.O., Odegbemi O.B.
Q4
Egyptian Journal of Medical Human Genetics
,
2025
,
citations by CoLab: 0
,

Open Access
,
PDF
|
Abstract
Abstract
Background
Type 2 Diabetes Mellitus (T2DM) is a significant global health concern characterised by insulin resistance and chronic hyperglycemia. Genetic factors, particularly variations in the CAPN-10 gene, have been implicated in T2DM susceptibility across diverse populations.
Aim and objective
This study aimed to conduct a meta-analysis to investigate the associations of single nucleotide polymorphisms (SNPs) in the CAPN-10 gene with T2DM among various populations, focusing specifically on Nigerian cohorts.
Materials and methods
A comprehensive literature search yielded 150 studies, from which 45 met inclusion criteria, encompassing approximately 25,000 individuals, including 10,000 diagnosed with T2DM. Statistical analyses assessed the association between CAPN-10 SNPs (UCSNP-43, UCSNP-19, UCSNP-63) and T2DM risk.
Results
A significant association was observed for UCSNP-43 (rs3792267) with T2DM (OR 1.50; 95% CI 1.28–1.75; p < 0.001), particularly in urban Nigerian populations. UCSNP-19 (rs3842570) also showed a moderate association (OR 1.35; 95% CI 1.10–1.66; p = 0.01), especially in South-West Nigeria. No significant association was found for UCSNP-63 (OR 1.15; 95% CI 0.90–1.45; p = 0.30).
Conclusion
The findings indicate that CAPN-10 SNPs, particularly UCSNP-43 and UCSNP-19, contribute to T2DM susceptibility in Nigerian populations, emphasising the importance of genetic screening for personalised interventions in diabetes management.
Top-100
Citing journals
5
10
15
20
25
30
35
40
|
|
Sleep and Vigilance
36 citations, 4.8%
|
|
International Journal of Environmental Research and Public Health
19 citations, 2.53%
|
|
Journal of Clinical Medicine
17 citations, 2.27%
|
|
COVID-19 and Sleep: A Global Outlook
15 citations, 2%
|
|
Frontiers in Psychology
14 citations, 1.87%
|
|
Sleep Medicine
14 citations, 1.87%
|
|
Journal of Sleep Research
13 citations, 1.73%
|
|
Nature and Science of Sleep
12 citations, 1.6%
|
|
Cureus
12 citations, 1.6%
|
|
Frontiers in Public Health
10 citations, 1.33%
|
|
Scientific Reports
10 citations, 1.33%
|
|
Frontiers in Neurology
9 citations, 1.2%
|
|
Healthcare
8 citations, 1.07%
|
|
Journal of Clinical Sleep Medicine
7 citations, 0.93%
|
|
Sleep
6 citations, 0.8%
|
|
Current Sleep Medicine Reports
6 citations, 0.8%
|
|
Sleep Medicine Clinics
6 citations, 0.8%
|
|
Heliyon
6 citations, 0.8%
|
|
Sleep and Breathing
6 citations, 0.8%
|
|
Brain Sciences
5 citations, 0.67%
|
|
BMC Psychiatry
5 citations, 0.67%
|
|
Chronobiology International
5 citations, 0.67%
|
|
Frontiers in Neuroscience
5 citations, 0.67%
|
|
Diseases
5 citations, 0.67%
|
|
Health Science Reports
5 citations, 0.67%
|
|
Journal of Personalized Medicine
4 citations, 0.53%
|
|
PeerJ
4 citations, 0.53%
|
|
BMC Public Health
4 citations, 0.53%
|
|
Clinical Medicine Insights: Endocrinology and Diabetes
3 citations, 0.4%
|
|
Indian Journal of Psychiatry
3 citations, 0.4%
|
|
Neuroscience and Biobehavioral Reviews
3 citations, 0.4%
|
|
BMJ Open
3 citations, 0.4%
|
|
Frontiers in Psychiatry
3 citations, 0.4%
|
|
Epilepsy and Behavior
3 citations, 0.4%
|
|
Journal of Rational - Emotive and Cognitive - Behavior Therapy
3 citations, 0.4%
|
|
Behavioral Sleep Medicine
3 citations, 0.4%
|
|
Computers in Biology and Medicine
3 citations, 0.4%
|
|
Wireless Personal Communications
3 citations, 0.4%
|
|
Journal of Ayurveda and Integrative Medicine
3 citations, 0.4%
|
|
Journal of Neurology
3 citations, 0.4%
|
|
Sensors
3 citations, 0.4%
|
|
Diagnostics
3 citations, 0.4%
|
|
Sleep and Biological Rhythms
3 citations, 0.4%
|
|
Medicine (United States)
3 citations, 0.4%
|
|
Biological Rhythm Research
3 citations, 0.4%
|
|
Sleep Medicine Reviews
3 citations, 0.4%
|
|
PLoS ONE
3 citations, 0.4%
|
|
IEEE Access
3 citations, 0.4%
|
|
Indian Journal of Sleep Medicine
3 citations, 0.4%
|
|
Journal of Medical Academics
3 citations, 0.4%
|
|
Medical Advancements in Aging and Regenerative Technologies
3 citations, 0.4%
|
|
Healthy Ageing and Longevity
3 citations, 0.4%
|
|
Cranio - Journal of Craniomandibular Practice
2 citations, 0.27%
|
|
Indian Journal of Otolaryngology and Head and Neck Surgery
2 citations, 0.27%
|
|
Health (United Kingdom)
2 citations, 0.27%
|
|
Sleep Health
2 citations, 0.27%
|
|
International Journal of Adolescent Medicine and Health
2 citations, 0.27%
|
|
International Journal of Behavioral Nutrition and Physical Activity
2 citations, 0.27%
|
|
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
2 citations, 0.27%
|
|
Biological Research for Nursing
2 citations, 0.27%
|
|
Digital Health
2 citations, 0.27%
|
|
Progress in Brain Research
2 citations, 0.27%
|
|
Journal of Business and Psychology
2 citations, 0.27%
|
|
International Journal of COPD
2 citations, 0.27%
|
|
Frontiers in Aging Neuroscience
2 citations, 0.27%
|
|
International Journal of Molecular Sciences
2 citations, 0.27%
|
|
Frontiers in Medicine
2 citations, 0.27%
|
|
Lecture Notes in Networks and Systems
2 citations, 0.27%
|
|
Advances in Experimental Medicine and Biology
2 citations, 0.27%
|
|
Respiratory Medicine
2 citations, 0.27%
|
|
Psicologia: Reflexao e Critica
2 citations, 0.27%
|
|
International Journal of Public Health
2 citations, 0.27%
|
|
Current Psychiatry Reports
2 citations, 0.27%
|
|
Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery
2 citations, 0.27%
|
|
F1000Research
2 citations, 0.27%
|
|
Thinking Skills and Creativity
2 citations, 0.27%
|
|
American Journal of Lifestyle Medicine
2 citations, 0.27%
|
|
Meditsinskiy sovet = Medical Council
2 citations, 0.27%
|
|
Annals of the National Academy of Medical Sciences (India)
2 citations, 0.27%
|
|
Industrial Psychiatry Journal
2 citations, 0.27%
|
|
Physiology and Behavior
1 citation, 0.13%
|
|
Proceedings of the National Academy of Sciences of the United States of America
1 citation, 0.13%
|
|
Journal of Psychosomatic Research
1 citation, 0.13%
|
|
BMC Medical Informatics and Decision Making
1 citation, 0.13%
|
|
German Journal of Exercise and Sport Research
1 citation, 0.13%
|
|
Srpski Arhiv Za Celokupno Lekarstvo
1 citation, 0.13%
|
|
Lecture Notes in Computer Science
1 citation, 0.13%
|
|
Dementia e Neuropsychologia
1 citation, 0.13%
|
|
Archives of Sexual Behavior
1 citation, 0.13%
|
|
Frontiers in Immunology
1 citation, 0.13%
|
|
Neuroscience and Behavioral Physiology
1 citation, 0.13%
|
|
Nursing in critical care
1 citation, 0.13%
|
|
Iranian Journal of Psychiatry and Behavioral Sciences
1 citation, 0.13%
|
|
Pain Management
1 citation, 0.13%
|
|
BMC Pulmonary Medicine
1 citation, 0.13%
|
|
Chest
1 citation, 0.13%
|
|
Life Sciences
1 citation, 0.13%
|
|
Indoor Air
1 citation, 0.13%
|
|
International Journal of Humanoid Robotics
1 citation, 0.13%
|
|
Risk Management and Healthcare Policy
1 citation, 0.13%
|
|
Show all (70 more) | |
5
10
15
20
25
30
35
40
|
Citing publishers
20
40
60
80
100
120
140
160
180
200
|
|
Springer Nature
183 citations, 24.4%
|
|
Elsevier
106 citations, 14.13%
|
|
MDPI
78 citations, 10.4%
|
|
Frontiers Media S.A.
56 citations, 7.47%
|
|
Wiley
44 citations, 5.87%
|
|
Taylor & Francis
41 citations, 5.47%
|
|
SAGE
22 citations, 2.93%
|
|
Institute of Electrical and Electronics Engineers (IEEE)
16 citations, 2.13%
|
|
Ovid Technologies (Wolters Kluwer Health)
14 citations, 1.87%
|
|
Oxford University Press
11 citations, 1.47%
|
|
The American Academy of Sleep Medicine
7 citations, 0.93%
|
|
Jaypee Brothers Medical Publishing
6 citations, 0.8%
|
|
5 citations, 0.67%
|
|
IGI Global
5 citations, 0.67%
|
|
Walter de Gruyter
4 citations, 0.53%
|
|
Georg Thieme Verlag KG
4 citations, 0.53%
|
|
PeerJ
4 citations, 0.53%
|
|
Cold Spring Harbor Laboratory
4 citations, 0.53%
|
|
BMJ
4 citations, 0.53%
|
|
Emerald
3 citations, 0.4%
|
|
EDP Sciences
3 citations, 0.4%
|
|
Public Library of Science (PLoS)
3 citations, 0.4%
|
|
Association for Computing Machinery (ACM)
3 citations, 0.4%
|
|
Medknow
3 citations, 0.4%
|
|
Bentham Science Publishers Ltd.
2 citations, 0.27%
|
|
Spandidos Publications
2 citations, 0.27%
|
|
Mark Allen Group
2 citations, 0.27%
|
|
SciELO
2 citations, 0.27%
|
|
Remedium, Ltd.
2 citations, 0.27%
|
|
Media Sphere Publishing House
2 citations, 0.27%
|
|
F1000 Research
2 citations, 0.27%
|
|
IntechOpen
2 citations, 0.27%
|
|
Cambridge University Press
1 citation, 0.13%
|
|
World Scientific
1 citation, 0.13%
|
|
IOS Press
1 citation, 0.13%
|
|
American Chemical Society (ACS)
1 citation, 0.13%
|
|
Pleiades Publishing
1 citation, 0.13%
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 citation, 0.13%
|
|
American Association for the Advancement of Science (AAAS)
1 citation, 0.13%
|
|
Mary Ann Liebert
1 citation, 0.13%
|
|
Associacao Neurologia Cognitiva e do Comportamento
1 citation, 0.13%
|
|
Institute for Operations Research and the Management Sciences (INFORMS)
1 citation, 0.13%
|
|
Indian Academy of Neurosciences
1 citation, 0.13%
|
|
American Medical Association (AMA)
1 citation, 0.13%
|
|
Society for Neuroscience
1 citation, 0.13%
|
|
European Respiratory Society (ERS)
1 citation, 0.13%
|
|
American Association of Clinical Endocrinology
1 citation, 0.13%
|
|
Associacao Brasileira de Psiquiatria Biologica
1 citation, 0.13%
|
|
Korean Society of Nursing Science
1 citation, 0.13%
|
|
Consilium Medicum
1 citation, 0.13%
|
|
American Dental Education Association
1 citation, 0.13%
|
|
Optical Society of India
1 citation, 0.13%
|
|
Hindawi Limited
1 citation, 0.13%
|
|
S. Karger AG
1 citation, 0.13%
|
|
Social Science Electronic Publishing
1 citation, 0.13%
|
|
JMIR Publications
1 citation, 0.13%
|
|
National Library of Serbia
1 citation, 0.13%
|
|
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology
1 citation, 0.13%
|
|
PAGEPress Publications
1 citation, 0.13%
|
|
Baishideng Publishing Group
1 citation, 0.13%
|
|
Brieflands
1 citation, 0.13%
|
|
Tech Science Press
1 citation, 0.13%
|
|
Hans Publishers
1 citation, 0.13%
|
|
Pharmaceutical Society of Korea
1 citation, 0.13%
|
|
Research Square Platform LLC
1 citation, 0.13%
|
|
The Korean College of Clinical Pharmacy
1 citation, 0.13%
|
|
Show all (36 more) | |
20
40
60
80
100
120
140
160
180
200
|
Publishing organizations
5
10
15
20
25
|
|
All India Institute of Medical Sciences, Rishikesh
24 publications, 8.05%
|
|
All India Institute of Medical Sciences, Delhi
19 publications, 6.38%
|
|
All India Institute of Medical Sciences, Bhopal
14 publications, 4.7%
|
|
Shree Guru Gobind Singh Tricentenary University
13 publications, 4.36%
|
|
Saveetha Institute of Medical and Technical Sciences
10 publications, 3.36%
|
|
University of Coimbra
10 publications, 3.36%
|
|
University of Aveiro
9 publications, 3.02%
|
|
King Saud University
8 publications, 2.68%
|
|
University of Lisbon
8 publications, 2.68%
|
|
Jamia Millia Islamia
7 publications, 2.35%
|
|
Sree Chitra Tirunal Institute for Medical Sciences and Technology
7 publications, 2.35%
|
|
Harvard University
6 publications, 2.01%
|
|
University of California, Davis
6 publications, 2.01%
|
|
University of Arizona
5 publications, 1.68%
|
|
University of Toronto
5 publications, 1.68%
|
|
Anahuac Mayab University
5 publications, 1.68%
|
|
Universidad Anáhuac
5 publications, 1.68%
|
|
Polytechnic Institute of Porto
5 publications, 1.68%
|
|
Jawaharlal Nehru University
4 publications, 1.34%
|
|
Armed Forces Medical College
4 publications, 1.34%
|
|
University of Bern
4 publications, 1.34%
|
|
National Autonomous University of Mexico
4 publications, 1.34%
|
|
Majmaah University
3 publications, 1.01%
|
|
University of Delhi
3 publications, 1.01%
|
|
All India Institute of Medical Sciences, Jodhpur
3 publications, 1.01%
|
|
Indian Institute of Technology Guwahati
3 publications, 1.01%
|
|
Islamic Azad University, Tehran
3 publications, 1.01%
|
|
JSS Academy of Higher Education & Research
3 publications, 1.01%
|
|
National Institute of Mental Health and Neurosciences
3 publications, 1.01%
|
|
NITTE University
3 publications, 1.01%
|
|
University of Geneva
3 publications, 1.01%
|
|
University of Oxford
3 publications, 1.01%
|
|
Johns Hopkins University
3 publications, 1.01%
|
|
Universidade Federal do Rio de Janeiro
3 publications, 1.01%
|
|
Swinburne University of Technology
3 publications, 1.01%
|
|
MSH Medical School Hamburg – University of Applied Sciences and Medical University
3 publications, 1.01%
|
|
Utrecht University
3 publications, 1.01%
|
|
KLS Gogte Institute of Technology
3 publications, 1.01%
|
|
Centro Hospitalar e Universitário de Coimbra
3 publications, 1.01%
|
|
Faculdade São Leopoldo Mandic
3 publications, 1.01%
|
|
University of Tennessee
3 publications, 1.01%
|
|
University of the Republic
3 publications, 1.01%
|
|
Mansoura University
3 publications, 1.01%
|
|
Jahangirnagar University
3 publications, 1.01%
|
|
Mashhad University of Medical Sciences
2 publications, 0.67%
|
|
Shiraz University of Medical Sciences
2 publications, 0.67%
|
|
Cleveland Clinic Abu Dhabi
2 publications, 0.67%
|
|
Isfahan University of Medical Sciences
2 publications, 0.67%
|
|
Shahid Beheshti University
2 publications, 0.67%
|
|
All India Institute of Medical Sciences, Raipur
2 publications, 0.67%
|
|
Banaras Hindu University
2 publications, 0.67%
|
|
Lovely Professional University
2 publications, 0.67%
|
|
National Institute of Technology Raipur
2 publications, 0.67%
|
|
Başkent University
2 publications, 0.67%
|
|
Bharath Institute of Higher Education and Research
2 publications, 0.67%
|
|
Arabian Gulf University
2 publications, 0.67%
|
|
Uppsala University
2 publications, 0.67%
|
|
Radboud University Nijmegen Medical Centre
2 publications, 0.67%
|
|
Manonmaniam Sundaranar University
2 publications, 0.67%
|
|
University of Helsinki
2 publications, 0.67%
|
|
University of Zurich
2 publications, 0.67%
|
|
Sultan Qaboos University
2 publications, 0.67%
|
|
Bern University of Applied Sciences
2 publications, 0.67%
|
|
University of Bergen
2 publications, 0.67%
|
|
Nottingham Trent University
2 publications, 0.67%
|
|
Haukeland University Hospital
2 publications, 0.67%
|
|
Deakin University
2 publications, 0.67%
|
|
Flinders University
2 publications, 0.67%
|
|
Barwon Health
2 publications, 0.67%
|
|
Boston University
2 publications, 0.67%
|
|
Reykjavik University
2 publications, 0.67%
|
|
University of California, Los Angeles
2 publications, 0.67%
|
|
University of California, San Francisco
2 publications, 0.67%
|
|
Pazmany Peter Catholic University
2 publications, 0.67%
|
|
Institute of Tropical Medicine Antwerp
2 publications, 0.67%
|
|
Pontifical Catholic University of Argentina
2 publications, 0.67%
|
|
Tilburg University
2 publications, 0.67%
|
|
Fordham University
2 publications, 0.67%
|
|
University of Cincinnati
2 publications, 0.67%
|
|
Dilla University
2 publications, 0.67%
|
|
Federal University of São Paulo
2 publications, 0.67%
|
|
University of Malta
2 publications, 0.67%
|
|
Lithuanian Sports University
2 publications, 0.67%
|
|
Nicolae Testemițanu State University of Medicine and Pharmacy
2 publications, 0.67%
|
|
Escola Bahiana de Medicina e Saude Publica
2 publications, 0.67%
|
|
Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
2 publications, 0.67%
|
|
Instituto Nacional de Rehabilitación
2 publications, 0.67%
|
|
Institute of Experimental Medicine
1 publication, 0.34%
|
|
N. P. Bechtereva Institute of the Human Brain of Russian Academy of Sciences
1 publication, 0.34%
|
|
Semey Medical University
1 publication, 0.34%
|
|
King Abdulaziz University
1 publication, 0.34%
|
|
University of Jeddah
1 publication, 0.34%
|
|
Shaqra University
1 publication, 0.34%
|
|
University of Tehran
1 publication, 0.34%
|
|
Shahid Beheshti University of Medical Sciences and Health Services
1 publication, 0.34%
|
|
Tabriz University of Medical Sciences
1 publication, 0.34%
|
|
Istanbul University
1 publication, 0.34%
|
|
Marmara University
1 publication, 0.34%
|
|
Istanbul Medipol University
1 publication, 0.34%
|
|
All India Institute of Medical Sciences, Bhubaneswar
1 publication, 0.34%
|
|
Show all (70 more) | |
5
10
15
20
25
|
Publishing organizations in 5 years
2
4
6
8
10
12
14
16
18
20
|
|
All India Institute of Medical Sciences, Rishikesh
19 publications, 8.76%
|
|
All India Institute of Medical Sciences, Delhi
14 publications, 6.45%
|
|
Shree Guru Gobind Singh Tricentenary University
13 publications, 5.99%
|
|
All India Institute of Medical Sciences, Bhopal
10 publications, 4.61%
|
|
Saveetha Institute of Medical and Technical Sciences
10 publications, 4.61%
|
|
University of Coimbra
9 publications, 4.15%
|
|
University of Aveiro
8 publications, 3.69%
|
|
University of Lisbon
7 publications, 3.23%
|
|
Jamia Millia Islamia
5 publications, 2.3%
|
|
Sree Chitra Tirunal Institute for Medical Sciences and Technology
5 publications, 2.3%
|
|
University of California, Davis
5 publications, 2.3%
|
|
King Saud University
4 publications, 1.84%
|
|
Harvard University
4 publications, 1.84%
|
|
University of Toronto
4 publications, 1.84%
|
|
Majmaah University
3 publications, 1.38%
|
|
University of Delhi
3 publications, 1.38%
|
|
All India Institute of Medical Sciences, Jodhpur
3 publications, 1.38%
|
|
Jawaharlal Nehru University
3 publications, 1.38%
|
|
Islamic Azad University, Tehran
3 publications, 1.38%
|
|
JSS Academy of Higher Education & Research
3 publications, 1.38%
|
|
National Institute of Mental Health and Neurosciences
3 publications, 1.38%
|
|
Armed Forces Medical College
3 publications, 1.38%
|
|
NITTE University
3 publications, 1.38%
|
|
University of Bern
3 publications, 1.38%
|
|
KLS Gogte Institute of Technology
3 publications, 1.38%
|
|
Faculdade São Leopoldo Mandic
3 publications, 1.38%
|
|
University of the Republic
3 publications, 1.38%
|
|
Jahangirnagar University
3 publications, 1.38%
|
|
Mashhad University of Medical Sciences
2 publications, 0.92%
|
|
Isfahan University of Medical Sciences
2 publications, 0.92%
|
|
Shahid Beheshti University
2 publications, 0.92%
|
|
Banaras Hindu University
2 publications, 0.92%
|
|
Lovely Professional University
2 publications, 0.92%
|
|
National Institute of Technology Raipur
2 publications, 0.92%
|
|
Başkent University
2 publications, 0.92%
|
|
Bharath Institute of Higher Education and Research
2 publications, 0.92%
|
|
Arabian Gulf University
2 publications, 0.92%
|
|
Uppsala University
2 publications, 0.92%
|
|
Radboud University Nijmegen Medical Centre
2 publications, 0.92%
|
|
Manonmaniam Sundaranar University
2 publications, 0.92%
|
|
University of Helsinki
2 publications, 0.92%
|
|
University of Zurich
2 publications, 0.92%
|
|
University of Geneva
2 publications, 0.92%
|
|
Sultan Qaboos University
2 publications, 0.92%
|
|
University of Oxford
2 publications, 0.92%
|
|
Bern University of Applied Sciences
2 publications, 0.92%
|
|
University of Bergen
2 publications, 0.92%
|
|
Nottingham Trent University
2 publications, 0.92%
|
|
Haukeland University Hospital
2 publications, 0.92%
|
|
Deakin University
2 publications, 0.92%
|
|
Flinders University
2 publications, 0.92%
|
|
Barwon Health
2 publications, 0.92%
|
|
Boston University
2 publications, 0.92%
|
|
Institute of Tropical Medicine Antwerp
2 publications, 0.92%
|
|
Pontifical Catholic University of Argentina
2 publications, 0.92%
|
|
National Autonomous University of Mexico
2 publications, 0.92%
|
|
Tilburg University
2 publications, 0.92%
|
|
Centro Hospitalar e Universitário de Coimbra
2 publications, 0.92%
|
|
Fordham University
2 publications, 0.92%
|
|
University of Tennessee
2 publications, 0.92%
|
|
Mansoura University
2 publications, 0.92%
|
|
Dilla University
2 publications, 0.92%
|
|
University of Malta
2 publications, 0.92%
|
|
Nicolae Testemițanu State University of Medicine and Pharmacy
2 publications, 0.92%
|
|
Escola Bahiana de Medicina e Saude Publica
2 publications, 0.92%
|
|
Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
2 publications, 0.92%
|
|
Anahuac Mayab University
2 publications, 0.92%
|
|
Universidad Anáhuac
2 publications, 0.92%
|
|
Polytechnic Institute of Porto
2 publications, 0.92%
|
|
Institute of Experimental Medicine
1 publication, 0.46%
|
|
N. P. Bechtereva Institute of the Human Brain of Russian Academy of Sciences
1 publication, 0.46%
|
|
Semey Medical University
1 publication, 0.46%
|
|
King Abdulaziz University
1 publication, 0.46%
|
|
University of Jeddah
1 publication, 0.46%
|
|
Shaqra University
1 publication, 0.46%
|
|
University of Tehran
1 publication, 0.46%
|
|
Shahid Beheshti University of Medical Sciences and Health Services
1 publication, 0.46%
|
|
Tabriz University of Medical Sciences
1 publication, 0.46%
|
|
Shiraz University of Medical Sciences
1 publication, 0.46%
|
|
Cleveland Clinic Abu Dhabi
1 publication, 0.46%
|
|
Marmara University
1 publication, 0.46%
|
|
Istanbul Medipol University
1 publication, 0.46%
|
|
All India Institute of Medical Sciences, Bhubaneswar
1 publication, 0.46%
|
|
All India Institute of Medical Sciences, Raipur
1 publication, 0.46%
|
|
All India Institute of Medical Sciences, Gorakhpur
1 publication, 0.46%
|
|
Istanbul University Cerrahpasa
1 publication, 0.46%
|
|
All India Institute of Medical Sciences, Kalyani
1 publication, 0.46%
|
|
All India Institute of Medical Sciences, Bibinagar
1 publication, 0.46%
|
|
Indian Institute of Technology Delhi
1 publication, 0.46%
|
|
Indian Institute of Technology Guwahati
1 publication, 0.46%
|
|
Indian Institute of Technology Jodhpur
1 publication, 0.46%
|
|
Indian Institute of Technology Indore
1 publication, 0.46%
|
|
Chandigarh University
1 publication, 0.46%
|
|
University of Kashmir
1 publication, 0.46%
|
|
National Institute of Technology Rourkela
1 publication, 0.46%
|
|
University of Health Sciences, Turkey
1 publication, 0.46%
|
|
Bharathidasan University
1 publication, 0.46%
|
|
Babasaheb Bhimrao Ambedkar University
1 publication, 0.46%
|
|
Jamia Hamdard
1 publication, 0.46%
|
|
Islamic Azad University North Tehran Branch
1 publication, 0.46%
|
|
Show all (70 more) | |
2
4
6
8
10
12
14
16
18
20
|
Publishing countries
20
40
60
80
100
120
140
160
|
|
India
|
India, 141, 47.32%
India
141 publications, 47.32%
|
USA
|
USA, 47, 15.77%
USA
47 publications, 15.77%
|
Canada
|
Canada, 26, 8.72%
Canada
26 publications, 8.72%
|
Portugal
|
Portugal, 19, 6.38%
Portugal
19 publications, 6.38%
|
Iran
|
Iran, 13, 4.36%
Iran
13 publications, 4.36%
|
Saudi Arabia
|
Saudi Arabia, 12, 4.03%
Saudi Arabia
12 publications, 4.03%
|
Turkey
|
Turkey, 11, 3.69%
Turkey
11 publications, 3.69%
|
Germany
|
Germany, 10, 3.36%
Germany
10 publications, 3.36%
|
Brazil
|
Brazil, 10, 3.36%
Brazil
10 publications, 3.36%
|
Mexico
|
Mexico, 10, 3.36%
Mexico
10 publications, 3.36%
|
United Kingdom
|
United Kingdom, 8, 2.68%
United Kingdom
8 publications, 2.68%
|
Japan
|
Japan, 8, 2.68%
Japan
8 publications, 2.68%
|
Australia
|
Australia, 7, 2.35%
Australia
7 publications, 2.35%
|
Switzerland
|
Switzerland, 7, 2.35%
Switzerland
7 publications, 2.35%
|
Egypt
|
Egypt, 5, 1.68%
Egypt
5 publications, 1.68%
|
Italy
|
Italy, 5, 1.68%
Italy
5 publications, 1.68%
|
Netherlands
|
Netherlands, 5, 1.68%
Netherlands
5 publications, 1.68%
|
Sweden
|
Sweden, 5, 1.68%
Sweden
5 publications, 1.68%
|
France
|
France, 4, 1.34%
France
4 publications, 1.34%
|
UAE
|
UAE, 4, 1.34%
UAE
4 publications, 1.34%
|
China
|
China, 3, 1.01%
China
3 publications, 1.01%
|
Bangladesh
|
Bangladesh, 3, 1.01%
Bangladesh
3 publications, 1.01%
|
Spain
|
Spain, 3, 1.01%
Spain
3 publications, 1.01%
|
Colombia
|
Colombia, 3, 1.01%
Colombia
3 publications, 1.01%
|
Uruguay
|
Uruguay, 3, 1.01%
Uruguay
3 publications, 1.01%
|
Ethiopia
|
Ethiopia, 3, 1.01%
Ethiopia
3 publications, 1.01%
|
Argentina
|
Argentina, 2, 0.67%
Argentina
2 publications, 0.67%
|
Bahrain
|
Bahrain, 2, 0.67%
Bahrain
2 publications, 0.67%
|
Belgium
|
Belgium, 2, 0.67%
Belgium
2 publications, 0.67%
|
Hungary
|
Hungary, 2, 0.67%
Hungary
2 publications, 0.67%
|
Jordan
|
Jordan, 2, 0.67%
Jordan
2 publications, 0.67%
|
Iceland
|
Iceland, 2, 0.67%
Iceland
2 publications, 0.67%
|
Lithuania
|
Lithuania, 2, 0.67%
Lithuania
2 publications, 0.67%
|
Malta
|
Malta, 2, 0.67%
Malta
2 publications, 0.67%
|
Moldova
|
Moldova, 2, 0.67%
Moldova
2 publications, 0.67%
|
Norway
|
Norway, 2, 0.67%
Norway
2 publications, 0.67%
|
Oman
|
Oman, 2, 0.67%
Oman
2 publications, 0.67%
|
Singapore
|
Singapore, 2, 0.67%
Singapore
2 publications, 0.67%
|
Finland
|
Finland, 2, 0.67%
Finland
2 publications, 0.67%
|
Russia
|
Russia, 1, 0.34%
Russia
1 publication, 0.34%
|
Kazakhstan
|
Kazakhstan, 1, 0.34%
Kazakhstan
1 publication, 0.34%
|
Ukraine
|
Ukraine, 1, 0.34%
Ukraine
1 publication, 0.34%
|
Bulgaria
|
Bulgaria, 1, 0.34%
Bulgaria
1 publication, 0.34%
|
Bosnia and Herzegovina
|
Bosnia and Herzegovina, 1, 0.34%
Bosnia and Herzegovina
1 publication, 0.34%
|
Greece
|
Greece, 1, 0.34%
Greece
1 publication, 0.34%
|
Denmark
|
Denmark, 1, 0.34%
Denmark
1 publication, 0.34%
|
Israel
|
Israel, 1, 0.34%
Israel
1 publication, 0.34%
|
Iraq
|
Iraq, 1, 0.34%
Iraq
1 publication, 0.34%
|
Ireland
|
Ireland, 1, 0.34%
Ireland
1 publication, 0.34%
|
Kuwait
|
Kuwait, 1, 0.34%
Kuwait
1 publication, 0.34%
|
Malaysia
|
Malaysia, 1, 0.34%
Malaysia
1 publication, 0.34%
|
Morocco
|
Morocco, 1, 0.34%
Morocco
1 publication, 0.34%
|
Nigeria
|
Nigeria, 1, 0.34%
Nigeria
1 publication, 0.34%
|
Pakistan
|
Pakistan, 1, 0.34%
Pakistan
1 publication, 0.34%
|
Slovakia
|
Slovakia, 1, 0.34%
Slovakia
1 publication, 0.34%
|
Sri Lanka
|
Sri Lanka, 1, 0.34%
Sri Lanka
1 publication, 0.34%
|
Show all (26 more) | |
20
40
60
80
100
120
140
160
|
Publishing countries in 5 years
20
40
60
80
100
120
|
|
India
|
India, 106, 48.85%
India
106 publications, 48.85%
|
USA
|
USA, 27, 12.44%
USA
27 publications, 12.44%
|
Canada
|
Canada, 18, 8.29%
Canada
18 publications, 8.29%
|
Portugal
|
Portugal, 15, 6.91%
Portugal
15 publications, 6.91%
|
Iran
|
Iran, 12, 5.53%
Iran
12 publications, 5.53%
|
Turkey
|
Turkey, 9, 4.15%
Turkey
9 publications, 4.15%
|
Saudi Arabia
|
Saudi Arabia, 8, 3.69%
Saudi Arabia
8 publications, 3.69%
|
United Kingdom
|
United Kingdom, 7, 3.23%
United Kingdom
7 publications, 3.23%
|
Japan
|
Japan, 7, 3.23%
Japan
7 publications, 3.23%
|
Brazil
|
Brazil, 6, 2.76%
Brazil
6 publications, 2.76%
|
Switzerland
|
Switzerland, 6, 2.76%
Switzerland
6 publications, 2.76%
|
Italy
|
Italy, 5, 2.3%
Italy
5 publications, 2.3%
|
Mexico
|
Mexico, 5, 2.3%
Mexico
5 publications, 2.3%
|
Germany
|
Germany, 4, 1.84%
Germany
4 publications, 1.84%
|
Australia
|
Australia, 4, 1.84%
Australia
4 publications, 1.84%
|
Egypt
|
Egypt, 4, 1.84%
Egypt
4 publications, 1.84%
|
Sweden
|
Sweden, 4, 1.84%
Sweden
4 publications, 1.84%
|
Bangladesh
|
Bangladesh, 3, 1.38%
Bangladesh
3 publications, 1.38%
|
Spain
|
Spain, 3, 1.38%
Spain
3 publications, 1.38%
|
Colombia
|
Colombia, 3, 1.38%
Colombia
3 publications, 1.38%
|
UAE
|
UAE, 3, 1.38%
UAE
3 publications, 1.38%
|
Uruguay
|
Uruguay, 3, 1.38%
Uruguay
3 publications, 1.38%
|
Ethiopia
|
Ethiopia, 3, 1.38%
Ethiopia
3 publications, 1.38%
|
France
|
France, 2, 0.92%
France
2 publications, 0.92%
|
China
|
China, 2, 0.92%
China
2 publications, 0.92%
|
Argentina
|
Argentina, 2, 0.92%
Argentina
2 publications, 0.92%
|
Bahrain
|
Bahrain, 2, 0.92%
Bahrain
2 publications, 0.92%
|
Belgium
|
Belgium, 2, 0.92%
Belgium
2 publications, 0.92%
|
Malta
|
Malta, 2, 0.92%
Malta
2 publications, 0.92%
|
Moldova
|
Moldova, 2, 0.92%
Moldova
2 publications, 0.92%
|
Netherlands
|
Netherlands, 2, 0.92%
Netherlands
2 publications, 0.92%
|
Norway
|
Norway, 2, 0.92%
Norway
2 publications, 0.92%
|
Oman
|
Oman, 2, 0.92%
Oman
2 publications, 0.92%
|
Singapore
|
Singapore, 2, 0.92%
Singapore
2 publications, 0.92%
|
Finland
|
Finland, 2, 0.92%
Finland
2 publications, 0.92%
|
Russia
|
Russia, 1, 0.46%
Russia
1 publication, 0.46%
|
Kazakhstan
|
Kazakhstan, 1, 0.46%
Kazakhstan
1 publication, 0.46%
|
Ukraine
|
Ukraine, 1, 0.46%
Ukraine
1 publication, 0.46%
|
Bulgaria
|
Bulgaria, 1, 0.46%
Bulgaria
1 publication, 0.46%
|
Bosnia and Herzegovina
|
Bosnia and Herzegovina, 1, 0.46%
Bosnia and Herzegovina
1 publication, 0.46%
|
Hungary
|
Hungary, 1, 0.46%
Hungary
1 publication, 0.46%
|
Greece
|
Greece, 1, 0.46%
Greece
1 publication, 0.46%
|
Denmark
|
Denmark, 1, 0.46%
Denmark
1 publication, 0.46%
|
Jordan
|
Jordan, 1, 0.46%
Jordan
1 publication, 0.46%
|
Iraq
|
Iraq, 1, 0.46%
Iraq
1 publication, 0.46%
|
Ireland
|
Ireland, 1, 0.46%
Ireland
1 publication, 0.46%
|
Kuwait
|
Kuwait, 1, 0.46%
Kuwait
1 publication, 0.46%
|
Malaysia
|
Malaysia, 1, 0.46%
Malaysia
1 publication, 0.46%
|
Morocco
|
Morocco, 1, 0.46%
Morocco
1 publication, 0.46%
|
Nigeria
|
Nigeria, 1, 0.46%
Nigeria
1 publication, 0.46%
|
Pakistan
|
Pakistan, 1, 0.46%
Pakistan
1 publication, 0.46%
|
Slovakia
|
Slovakia, 1, 0.46%
Slovakia
1 publication, 0.46%
|
Sri Lanka
|
Sri Lanka, 1, 0.46%
Sri Lanka
1 publication, 0.46%
|
Show all (23 more) | |
20
40
60
80
100
120
|
2 profile journal articles
Corlateanu Alexandru
🥼 🤝
67 publications,
1 044 citations
h-index: 13
1 profile journal article
Kamruzzaman Md
35 publications,
354 citations
h-index: 10